Orexin receptor 2 agonist reduces symptoms of narcolepsy type 1
Bookmark1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994)...
Read MoreSep 6, 2023
Bookmark1. In this randomized controlled trial, an oral orexin receptor 2 (OX2R) agonist (TAK-994)...
Read MoreSep 6, 2023
Bookmark1. In Brasil, Russia, India, China, and South Africa, the availability of breast cancer...
Read MoreSep 5, 2023
Bookmark1. The offspring of individuals consuming a Mediterranean diet or engaging in a...
Read MoreSep 4, 2023
Bookmark1. This analysis of a prospective cohort of moderate and late preterm (MLPT) children...
Read MoreSep 3, 2023
Bookmark1. For postpartum pain management, there is no overall increased risk of persistent opioid...
Read MoreAug 31, 2023
Bookmark1. In a cross-sectional study, adolescent survivors of childhood cancers were more...
Read MoreAug 31, 2023
Bookmark1. Complete response or remission was reported in 18% of patients who received a single...
Read MoreAug 30, 2023
Bookmark1. In this systematic review and network meta-analysis, aerobic exercise training, dynamic...
Read MoreAug 30, 2023
Bookmark1. Body weight reduction at week 72 was significantly greater with tirzepatide versus...
Read MoreAug 28, 2023
Bookmark1. For women with infertility on assisted reproductive technologies (ART), higher...
Read MoreAug 26, 2023
Bookmark1. In this randomized controlled trial, a high dose of GNT0003 gene therapy was associated...
Read MoreAug 25, 2023
Bookmark1. Mean MADRS change at week 6 was -8.2 in the active tDCS group versus -8.0 in the sham...
Read MoreAug 25, 2023
Bookmark1. In this randomized controlled trial, there were no significant differences in the...
Read MoreAug 25, 2023
Bookmark1. The risk of mortality from solid cancer, lagged by 10 years, is estimated to be...
Read MoreAug 24, 2023
Bookmark1. Patients with inappropriate hospital admission (IHA) experience twice more adverse...
Read MoreAug 23, 2023
Bookmark1. HbA1c and bodyweight reduction were greater in the retatrutide group compared to...
Read MoreAug 22, 2023
Bookmark1. In this cross-sectional study, there was a negative association between sleep duration...
Read MoreAug 22, 2023
Bookmark1. 5-year recurrence incidence was 2.5% at follow-up. 2. Overall survival at 5 years...
Read MoreAug 22, 2023
Bookmark1. Median progression-free survival was shown to be 27.7 months in the vorasidenib group...
Read MoreAug 19, 2023
Bookmark1. This phase 2, single-arm, multicenter trial found that in HER2-positive breast cancer...
Read More